Peptide reference
DSIP
Delta Sleep-Inducing Peptide ·Emideltide ·Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu nonapeptide
What cited sources report about DSIP
Delta Sleep-Inducing Peptide (DSIP), also known by the proposed INN Emideltide, is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood in the 1970s. The peptide is currently under review by the FDA Pharmacy Compounding Advisory Committee (PCAC), with a public meeting scheduled for July 23, 2026. As of the cited literature, DSIP has no FDA-approved indication and no marketing authorization in any major jurisdiction. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.
Rahman, Lee, and Seeds (2026) — JAAOS Global Research and Reviews
A 2026 narrative review published in the open-access global research journal of the American Academy of Orthopaedic Surgeons catalogued therapeutic peptides under discussion in orthopaedic contexts. The authors grouped DSIP with epithalon and pinealon under “recovery-enhancing agents” said to target circadian and mitochondrial regulators, and they observed that the cited preclinical literature has not been matched by adequately powered clinical trials.
Recovery-enhancing agents such as epithalon, delta sleep-inducing peptide, and pinealon target circadian and mitochondrial regulators… Although preclinical studies are promising, there is a current lack of clinical trials.
Mu et al. (2024) — Frontiers in Pharmacology
Researchers at Jilin University and Zunyi Medical University evaluated a DSIP-CBBBP (DSIP–crossing-the-blood-brain-barrier peptide) fusion construct in a PCPA-induced insomnia mouse model. The authors reported neurotransmitter modulation (5-HT, glutamate, dopamine, melatonin) and observed that the fusion construct produced a larger effect than free DSIP in their assays — they framed the work as a preclinical mechanism-of-action investigation rather than a human-efficacy claim.
DSIP-CBBBP demonstrates a capacity to modulate neurotransmitter levels, indicated by changes in 5-HT, glutamate, DA, and melatonin.
Zhang et al. (2017) — Protein and Peptide Letters
A preclinical study from Lanzhou University of Technology expressed a TAT–HSA–DSIP fusion protein in Pichia pastoris and evaluated it in a pentobarbital-induced sleep test in mice at 0.5, 1, and 2 mg/kg subcutaneously. The authors reported dose-dependent reductions in sleep latency and prolongation of sleep duration in the treated animals. They explicitly observed that, despite DSIP’s age, little has been established about its pharmacological effect on insomnia.
Delta sleep-inducing peptide (DSIP) is a nonapeptide that could promote sleep through the induction of slow wave sleep. However, little is known about the pharmacological effect of DSIP on insomnia.
PubChem CID 68815 — National Center for Biotechnology Information
The PubChem compound record for delta sleep-inducing peptide catalogues the nonapeptide sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, aggregates synonym sets (including DSIP and Emideltide-related identifiers), and links out to the underlying chemical and biological literature.
Coverage notes
Despite roughly five decades of published DSIP research, the cited modern reviews (Rahman 2026; Zhang 2017) report that the human pharmacological literature on DSIP for insomnia is sparse and that no large, contemporary, blinded clinical efficacy trial is publicly indexed. No FDA-approved indication exists. This page will be updated when the July 2026 PCAC briefing materials are released.